Price$1.96-1.29 (-39.60%)
2026-04-212026-07-24
News · 26 weeks32+25%
2026-02-012026-07-26
Mix1790d
- Market6(35%)
- SEC Filings5(29%)
- Other4(24%)
- Analyst2(12%)
Latest news
25 items- PREvotec Selects Navan to Unify Global Travel, Payments, and Expense ManagementGlobal drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ:NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ:EVO, Frankfurt Prime Standard: EVT)), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life scienc
- ANALYSTEvotec SE downgraded by BerenbergBerenberg downgraded Evotec SE from Buy to Hold
- ANALYSTEvotec SE downgraded by TD Cowen with a new price targetTD Cowen downgraded Evotec SE from Buy to Hold and set a new price target of $2.00
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PRAd hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 OutlookDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial results for the second quarter and first half of 2026 will be published on August 13, 2026, as scheduled.Based on preliminary figures, Evotec expects Group revenues for the first half of 2026 of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million. As of June 30, 2026, liquidity is expected to amount to approx
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PRJust - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for BiologicsExpands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platformEnables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturingModular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturingSEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enable
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PREvotec Reports Results of the Annual General Meeting 202611.06.2026 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement. All agenda items adoptedDieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory BoardDieter Weinand appointed Chairman of the Supervisory BoardDr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory BoardHAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO, Frankfurt Prime Standard: EVT)) today announced the results of its Annual General Meeting.All agenda items put to vote were adopted by the Company's shareholders with the required majority.Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual Ge
- NEWSEvotec Appoints Rui Wang as Head of Global In Silico and AIHAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions. In his role, Mr. Wang will spearhead the integration of computational science and data-driven decision-making across the R&D operation, with the goal of creating enterprise-scale solutions that ensure AI and in silico science become key pillars of the Evotec commercial val
- NEWSEvotec SE Successfully Placed €116.1 Million Convertible BondsNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. HAMBURG, GERMANY / ACCESS Newswire / May 12, 2026 / Evotec SE (the "Company" or "Evotec") (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) placed today senior unsecured convertible bonds due 2033, convertible into new and/or existing no-par value ordinary bearer shares of the Company (the "Shares"), in an aggregate principal amount of €116.1 million (the "Bonds"). The pre-emption rights of the shareholders were exc
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with AlmirallJoint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelinesCollaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multi‑target drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at developing novel treatments for immune‑mediated inflammatory skin diseases with high unmet medical need.The nomination marks an importa
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Receives Grants to Advance Tuberculosis TreatmentGrants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testingNew funding from the Gates Foundation extends Evotec's commitment to create more effective tuberculosis treatment regimens HAMBURG, GERMANY / ACCESS Newswire / April 30, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the foundation, amounting to $4.9 million over 25 months and $5 million over 24 months. The new funding underscores Evotec's commitment to translating inno
- NEWSEvotec Announces New Nomination to Board of DirectorsNomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilitiesConclusion of cooperation agreement with MAK Capital following constructive discussions, reflecting Evotec's commitment to open shareholder dialogueAnnual General Meeting to vote on the appointments of Supervisory Board members and proposed expansion of Supervisory Board, supporting effective oversight and long‑term value creation HAMBURG, GERMANY / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt:EVT) today announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company's upcomi
- NEWSEvotec SE to Announce First Quarter 2026 Results on May 6, 2026HAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO, Frankfurt Prime Standard: EVT)) will hold a webcast and conference call to announce its financial results for the first quarter 2026 and provide a business update on Wednesday, May 6, 2026. The conference call will be held in English.Webcast detailsDate: Wednesday, May 6, 2026Time: 2.00 pm CEST (12.00 pm GMT, 8.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com.Conference call detailsTo join the conference call, please pre-register via this link. You will then receive a confirmation
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Announces Chief Financial Officer TransitionPaul Hitchin to step down as of April 30, 2026Claire Hinshelwood appointed to CFO role as of May 1, 2026 HAMBURG, DE / ACCESS Newswire / April 24, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that Chief Financial Officer (CFO) Paul Hitchin will step down on April 30, 2026, for personal reasons unrelated to the company. The Supervisory Board has accepted Mr. Hitchin's decision and expressed deep appreciation for his leadership and significant contributions to the company. Since March 1, 2025, he successfully led Evotec through a significant financial and strategic evolution.Mr. Hitchin will be succeeded by Claire Hinshelwood, effective May 1, 2026. Ms. Hinshelwo
- ANALYSTH.C. Wainwright resumed coverage on Evotec SE with a new price targetH.C. Wainwright resumed coverage of Evotec SE with a rating of Buy and set a new price target of $7.00
- NEWSEvotec Appoints Dr. Ingrid Müller as Chief Operating OfficerWill play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiativeBrings more than 20 years of international leadership experience across operations, transformation, strategy, supply, procurement and R&D integrationHAMBURG, DE / ACCESS Newswire / April 15, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ingrid Müller as Chief Operating Officer (COO). Dr. Müller will be joining Evotec's Management Board, effective May 1, 2026. She brings to Evotec more than 20 years of international leadership experience in the life scien
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECSEC Form 20-F filed by Evotec SE20-F - Evotec SE (0001412558) (Filer)
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- NEWSEvotec Nominates Dieter Weinand as Supervisory Board ChairmanStrengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitabilityIndustry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, commercial, operational and strategic rolesHAMBURG, DE / ACCESS Newswire / April 7, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced that the Supervisory Board of Evotec SE has proposed the election of Dieter Weinand, M.S. as Chairman of the Supervisory Board at the June 11, 2026, Annual General Meeting. The nomination reflects Evotec's continued commitment to strengthening commercial execu
EVO FAQ
7 questionsWhat does Evotec SE do?
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin...Where does EVO stock trade?
Evotec SE (EVO) is listed on NASDAQ.What sector and industry is EVO in?
Evotec SE operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Evotec SE go public?
Evotec SE (EVO) completed its IPO in 2021.What are analysts saying about EVO?
Evotec SE has had 8 recent analyst actions on file. The most recent action was from Berenberg: Hold on 2026-07-16. Recent price targets range from $200.00 to $700.00.What companies are similar to EVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EVO side-by-side with any of them on Quantisnow.How can I track EVO on Quantisnow?
Quantisnow aggregates Evotec SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVO to receive live email and push alerts on every new disclosure.